Document is current
Any future updates will be listed below
-
Authors
Mascarenhas, John https://orcid.org/0000-0002-8400-0483
Gleitz, Hélène F. E.
Chifotides, Helen T. https://orcid.org/0000-0001-8044-4960
Harrison, Claire N.
Verstovsek, Srdan https://orcid.org/0000-0002-6912-8569
Vannucchi, Alessandro Maria
Rampal, Raajit K. https://orcid.org/0000-0002-0355-6368
Kiladjian, Jean-Jacques https://orcid.org/0000-0002-8121-438X
Vainchenker, William https://orcid.org/0000-0003-4705-202X
Hoffman, Ronald https://orcid.org/0000-0001-6564-6732
Schneider, Rebekka K.
List, Alan F.
- License Information
-
More Information
Article History
Received: 30 September 2022
Revised: 10 November 2022
Accepted: 14 November 2022
First Online: 24 November 2022
Competing interests
: JM receives research funding paid to his institution from Incyte, CTI Bio, Novartis, PharmaEssentia, Merck, Kartos, Geron, BMS, Roche, and consulting fees from Incyte, CTI Bio, Novartis, Roche, BMS, Celgene, Geron, PharmaEssentia, Morphosys, Sierra Oncology, GSK, Galecto, Karyopharm, Kartos, and Imago. HFEG has nothing to declare. HTC has nothing to declare. CNH received research funding paid to the institutional from Novartis, Celgene, and Constellation Pharmaceuticals, MorphoSys and consulting fees from Keros, Galecto, AOP and Roche, Novartis, Celgene, CTI BioPharma, AbbVie, Janssen, Geron, Promedior, AbbVie, AOP Pharma. SV receives research funding paid to the institution from Incyte, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Blueprint Medicines, Novartis, Sierra Oncology, PharmaEssentia, Protagonist Therapeutics, Kartos Galecto and consulting fees from Constellation, Sierra Oncology, Incyte, Novartis, BMS, Kartos, Galecto, Protagonist. AMV receives consulting fees from Novartis, BMS, Incyte, Blueprint, and Abbvie. RKR receives research funding paid to the institution from Research funding: Constellation, Incyte, Stemline, Zentalis and consulting feels from Constellation, Incyte, Celgene/BMS, Novartis, Promedior, CTI, Jazz Pharmaceuticals, Blueprint, Stemline, Galecto, Pharmaessentia, Abbvie, Sierra Oncology, Disc Medicines, Sunimoto Dainippon, Zentalis. JJK receives consulting fees from Novartis, Abbvie, BMS, Sierra Oncology, CTI Biopharma, PharmaEssentia, AOP Orphan. WV has nothing to disclose. RH received research grant funding to the institution from BMS, Citi Bio, Curis, Inc., Genentech, Kartos Therapeutics, Kymera Therapeutics, OncoMyx Therapeutics, Protagonist Therapeutics, Repare Therapeutics, Scholar Rock, Translational Drug Development (TD2), Turning Point Therapeutics and consulting fees from AbbVie, Ionis Pharmaceuticals, Novartis, Protagonist Therapeutics, Silence Therapeutics. RKS has nothing to declare. AFL receives consulting fees from Halia Therapeutic, Rigel Pharmaceuticals, CTI Biopharma, and Aileron Inc.
